GSK Pharma Q2 profit rises 31% as revenue grows 21%
GSK Pharma reported a 31% rise in Q2 profit to Rs 334.62 crore, with revenue growing 21% to Rs 1,179.91 crore. The increase was driven by higher operating revenue and other income, including Rs 42.09 crore from an income-tax refund. For the first half, revenue reached Rs 2,104.33 crore, and profit after tax was Rs 587.95 crore.
How this was made
The 30-second read
Why it matters
The earnings beat could drive short‑term buying interest, but rising expenses and cash outflows may limit upside.
Market read
Primary earnings disclosure for a large-cap pharma company; likely short‑term price impact.
What to watch
Higher inventory expenses and lower cash balances may temper enthusiasm.
Background
GSK Pharma is a major Indian pharmaceutical company; the Q2 FY27 results were released on 3 Nov 2026.
Ticker impact
GSK Pharma reported Q2 FY27 profit after tax of Rs 334.62 cr, up 31% YoY, with revenue up 21%, a fresh earnings disclosure.
potential upside as market prices in the earnings beat
The company posted significantly higher profit and revenue than the prior year, indicating improved operating performance.
Market effects
Pharma sector may see modest lift as a large peer demonstrates strong earnings momentum.
Indian market participants may view the results as a positive signal for domestic pharma exposure.
Limited; impact confined to GSK and its immediate peers.
Counterpoint
If the earnings beat is already priced in, the stock could face profit‑taking pressure.
Key entities
- companyGSK Pharma
Indian pharmaceutical firm reporting Q2 FY27 results.
